APA (7th ed.) Citation

Yang, S., Pang, Y., Wang, Z., Zhang, B., Liu, Z., Chen, E., . . . Xie, F. (2022). Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era. Cancer medicine (Malden, MA), 11(4), 1109-1118. https://doi.org/10.1002/cam4.4520

Chicago Style (17th ed.) Citation

Yang, Shan‐Shan, Ya‐Jun Pang, Zhi‐Qiang Wang, Bao‐Yu Zhang, Zhi‐Qiao Liu, En‐Ni Chen, Pu‐Yun OuYang, and Fang‐Yun Xie. "Development and Prospective Validation of a Risk Score Model in Guiding Individualized Concurrent Chemoradiotherapy in Stage II Nasopharyngeal Carcinoma in Intensity‐modulated Radiotherapy Era." Cancer Medicine (Malden, MA) 11, no. 4 (2022): 1109-1118. https://doi.org/10.1002/cam4.4520.

MLA (9th ed.) Citation

Yang, Shan‐Shan, et al. "Development and Prospective Validation of a Risk Score Model in Guiding Individualized Concurrent Chemoradiotherapy in Stage II Nasopharyngeal Carcinoma in Intensity‐modulated Radiotherapy Era." Cancer Medicine (Malden, MA), vol. 11, no. 4, 2022, pp. 1109-1118, https://doi.org/10.1002/cam4.4520.